The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries.
Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today. The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback